Literature DB >> 22229047

Impact of protein binding on the analytical detectability and anticancer activity of thymoquinone.

Nahed El-Najjar, Raimo A Ketola, Teemu Nissilä, Timo Mauriala, Maxim Antopolsky, Janne Jänis, Hala Gali-Muhtasib, Arto Urtti, Heikki Vuorela.   

Abstract

UNLABELLED: Thymoquinone (TQ), an active component of Nigella sativa L., is known to have anti-cancer and anti-inflammatory effects; however, no studies on its analytical detection in serum and its protein binding have been published. Using high performance liquid chromatography analysis, we show that the average recovery of TQ from serum is 2.5% at 10 μg/ml of TQ and 72% at 100 μg/ml. The low recovery of TQ from serum is due to its extensive binding to plasma proteins, as more than 99% of TQ was bound within 30 min of incubation. The binding of TQ to the major plasma proteins, bovine serum albumin (BSA) and alpha -1 acid glycoprotein (AGP), was studied and found to be 94.5 ± 1.7% for BSA and 99.1 ± 0.1% for AGP. Mass spectrometric analysis revealed that TQ was bound covalently to BSA, specifically on Cyst-34. Using WST-1 proliferation assay, we showed that BSA plays a protective role against TQ-induced cell death; pre-incubation with BSA prevented TQ from exerting its anti-proliferative effects against DLD-1 and HCT-116 human colon cancer cells. On the other hand, binding of TQ to AGP did not alter its anti-proliferative activity against both cell lines. When TQ was pre-incubated with AGP prior to the addition of BSA, the activity of TQ against DLD-1 was maintained, suggesting that AGP prevented the binding of TQ to BSA. This is the first time the covalent binding and inhibitory effect of BSA on TQ is documented. These data offer new grounds for TQ future pharmacokinetic analysis in vivo. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s12154-010-0052-4) contains supplementary material, which is available to authorized users.

Entities:  

Keywords:  Anticancer activity; Mass spectrometry; Protein binding; Serum; Thymoquinone

Year:  2011        PMID: 22229047      PMCID: PMC3124627          DOI: 10.1007/s12154-010-0052-4

Source DB:  PubMed          Journal:  J Chem Biol        ISSN: 1864-6158


  34 in total

1.  Thymoquinone, a potential therapeutic agent of Nigella sativa, binds to site I of human serum albumin.

Authors:  G Lupidi; A Scire; E Camaioni; K H Khalife; G De Sanctis; F Tanfani; E Damiani
Journal:  Phytomedicine       Date:  2010-02-18       Impact factor: 5.340

Review 2.  Albumin: biochemical properties and therapeutic potential.

Authors:  Gregory J Quinlan; Greg S Martin; Timothy W Evans
Journal:  Hepatology       Date:  2005-06       Impact factor: 17.425

3.  Inhibition of benzo(a)pyrene-induced forestomach carcinogenesis in mice by thymoquinone.

Authors:  O A Badary; O A Al-Shabanah; M N Nagi; A C Al-Rikabi; M M Elmazar
Journal:  Eur J Cancer Prev       Date:  1999-10       Impact factor: 2.497

Review 4.  Binding of drugs by albumin and plasma protein.

Authors:  J J Vallner
Journal:  J Pharm Sci       Date:  1977-04       Impact factor: 3.534

5.  Site-specific binding of quinones to proteins through thiol addition and addition-elimination reactions.

Authors:  Wen-Wu Li; Jürgen Heinze; Wolfgang Haehnel
Journal:  J Am Chem Soc       Date:  2005-05-04       Impact factor: 15.419

6.  High performance liquid chromatographic analysis of the pharmacologically active quinones and related compounds in the oil of the black seed (Nigella sativa L.).

Authors:  O A Ghosheh; A A Houdi; P A Crooks
Journal:  J Pharm Biomed Anal       Date:  1999-04       Impact factor: 3.935

7.  A comparison of the morphological changes associated with conventional and sustained treatment with pigallocatechin3gallate, thymoquinone, and tannic acid on lncap cells.

Authors:  La'toya Ross Richards; Pamala Jones; Hamed Benghuzzi; Michelle Tucci
Journal:  Biomed Sci Instrum       Date:  2008

Review 8.  Pharmacological and toxicological properties of Nigella sativa.

Authors:  B H Ali; Gerald Blunden
Journal:  Phytother Res       Date:  2003-04       Impact factor: 5.878

9.  Thymoquinone reduces mouse colon tumor cell invasion and inhibits tumor growth in murine colon cancer models.

Authors:  Hala Gali-Muhtasib; Matthias Ocker; Doerthe Kuester; Sabine Krueger; Zeina El-Hajj; Antje Diestel; Matthias Evert; Nahed El-Najjar; Brigitte Peters; Abdo Jurjus; Albert Roessner; Regine Schneider-Stock
Journal:  J Cell Mol Med       Date:  2008 Jan-Feb       Impact factor: 5.310

10.  Identification of the in vitro metabolites of 3,4-dihydro-2,2-dimethyl-2H-naphthol[1,2-b]pyran-5,6-dione (ARQ 501; beta-lapachone) in whole blood.

Authors:  Xiu-Sheng Miao; Pengfei Song; Ronald E Savage; Caiyun Zhong; Rui-Yang Yang; Darin Kizer; Hui Wu; Erika Volckova; Mark A Ashwell; Jeffrey G Supko; Xiaoying He; Thomas C K Chan
Journal:  Drug Metab Dispos       Date:  2008-01-07       Impact factor: 3.579

View more
  14 in total

1.  A stable isotope-labeled internal standard is essential for correcting for the interindividual variability in the recovery of lapatinib from cancer patient plasma in quantitative LC-MS/MS analysis.

Authors:  Jianmei Wu; Richard Wiegand; Patricia LoRusso; Jing Li
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2013-10-16       Impact factor: 3.205

2.  Enriched pharmacokinetic behavior and antitumor efficacy of thymoquinone by liposomal delivery.

Authors:  Hari Krishnareddy Rachamalla; Santanu Bhattacharya; Ajaz Ahmad; Kathyayani Sridharan; Vijay Sagar Madamsetty; Sujan Kumar Mondal; Enfeng Wang; Shamit K Dutta; Basit L Jan; Sudhakar Jinka; Madan Mohan Chandra Sekhar Jaggarapu; Venu Yakati; Debabrata Mukhopadhyay; Khalid M Alkharfy; Rajkumar Banerjee
Journal:  Nanomedicine (Lond)       Date:  2021-03-26       Impact factor: 5.307

3.  Anticancer Activity of Thymoquinone Cubic Phase Nanoparticles Against Human Breast Cancer: Formulation, Cytotoxicity and Subcellular Localization.

Authors:  Mohammed M Mehanna; Rana Sarieddine; Jana K Alwattar; Racha Chouaib; Hala Gali-Muhtasib
Journal:  Int J Nanomedicine       Date:  2020-12-01

Review 4.  Thymoquinone: A Promising Natural Compound with Potential Benefits for COVID-19 Prevention and Cure.

Authors:  Osama A Badary; Marwa S Hamza; Rajiv Tikamdas
Journal:  Drug Des Devel Ther       Date:  2021-05-03       Impact factor: 4.162

Review 5.  Antitumor activity of monoterpenes found in essential oils.

Authors:  Marianna Vieira Sobral; Aline Lira Xavier; Tamires Cardoso Lima; Damião Pergentino de Sousa
Journal:  ScientificWorldJournal       Date:  2014-10-14

6.  The Neuroprotective Effects of Thymoquinone: A Review.

Authors:  Tahereh Farkhondeh; Saeed Samarghandian; Ali Mohammad Pourbagher Shahri; Fariborz Samini
Journal:  Dose Response       Date:  2018-04-11       Impact factor: 2.658

7.  Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selection.

Authors:  Fiona Collinson; Michelle Hutchinson; Rachel A Craven; David A Cairns; Alexandre Zougman; Tobias C Wind; Narinder Gahir; Michael P Messenger; Sharon Jackson; Douglas Thompson; Cybil Adusei; Jonathan A Ledermann; Geoffrey Hall; Gordon C Jayson; Peter J Selby; Rosamonde E Banks
Journal:  Clin Cancer Res       Date:  2013-08-09       Impact factor: 12.531

8.  Thymoquinone inhibits autophagy and induces cathepsin-mediated, caspase-independent cell death in glioblastoma cells.

Authors:  Ira O Racoma; Walter Hans Meisen; Qi-En Wang; Balveen Kaur; Altaf A Wani
Journal:  PLoS One       Date:  2013-09-09       Impact factor: 3.240

Review 9.  Thymoquinone in the clinical treatment of cancer: Fact or fiction?

Authors:  Majed M Abukhader
Journal:  Pharmacogn Rev       Date:  2013-07

Review 10.  Therapeutic Potential and Pharmaceutical Development of Thymoquinone: A Multitargeted Molecule of Natural Origin.

Authors:  Sameer N Goyal; Chaitali P Prajapati; Prashant R Gore; Chandragouda R Patil; Umesh B Mahajan; Charu Sharma; Sandhya P Talla; Shreesh K Ojha
Journal:  Front Pharmacol       Date:  2017-09-21       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.